Your browser is no longer supported. Please, upgrade your browser.
BNTX [NASD]
BioNTech SE
Index- P/E13.78 EPS (ttm)18.95 Insider Own1.18% Shs Outstand244.06M Perf Week7.44%
Market Cap64.00B Forward P/E6.96 EPS next Y37.49 Insider Trans0.00% Shs Float215.94M Perf Month-27.31%
Income4.72B PEG- EPS next Q10.39 Inst Own16.70% Short Float1.06% Perf Quarter6.49%
Sales9.01B P/S7.10 EPS this Y107.10% Inst Trans0.97% Short Ratio0.53 Perf Half Y67.17%
Book/sh26.05 P/B10.02 EPS next Y7.93% ROA95.10% Target Price332.87 Perf Year177.49%
Cash/sh4.33 P/C60.33 EPS next 5Y- ROE158.10% 52W Range75.35 - 464.00 Perf YTD220.28%
Dividend- P/FCF- EPS past 5Y- ROI4.90% 52W High-43.06% Beta-
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin85.00% 52W Low250.65% ATR16.98
Employees2500 Current Ratio2.70 Sales Q/Q12630.20% Oper. Margin76.20% RSI (14)43.04 Volatility3.82% 5.82%
OptionableYes Debt/Eq0.22 EPS Q/Q- Profit Margin52.40% Rel Volume1.46 Prev Close261.09
ShortableYes LT Debt/Eq0.09 EarningsNov 09 BMO Payout0.00% Avg Volume4.33M Price264.20
Recom2.50 SMA20-3.56% SMA50-18.47% SMA20026.78% Volume2,387,453 Change1.19%
Oct-07-21Initiated Jefferies Hold $230
Aug-11-21Upgrade Bryan Garnier Neutral → Buy $451
Jul-19-21Resumed Wolfe Research Outperform $248
Jun-16-21Downgrade Redburn Neutral → Sell $146
May-18-21Initiated Goldman Neutral $173
May-11-21Downgrade Bryan Garnier Buy → Neutral $135 → $206
Dec-01-20Downgrade BofA Securities Buy → Neutral $123 → $126
Aug-03-20Resumed Berenberg Buy $98
Jul-21-20Upgrade BofA Securities Neutral → Buy $71 → $105
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Nov-04-19Initiated UBS Buy $21
Nov-04-19Initiated SVB Leerink Outperform
Nov-04-19Initiated JP Morgan Overweight $23
Oct-19-21 06:34AM  
05:52AM  
Oct-18-21 07:29PM  
01:17PM  
10:29AM  
Oct-16-21 09:01AM  
Oct-15-21 05:47PM  
04:28PM  
02:51PM  
10:01AM  
08:18AM  
06:55AM  
Oct-14-21 05:45PM  
05:45PM  
04:23PM  
03:56PM  
02:37PM  
12:48PM  
Oct-13-21 04:24PM  
02:32PM  
06:32AM  
06:30AM  
Oct-12-21 05:31PM  
02:24PM  
11:30AM  
04:00AM  
Oct-11-21 06:14PM  
03:10PM  
Oct-08-21 08:00PM  
04:27PM  
02:32PM  
10:07AM  
09:24AM  
Oct-07-21 11:16PM  
04:23PM  
04:05PM  
01:48PM  
10:56AM  
10:46AM  
10:01AM  
08:46AM  
08:40AM  
08:11AM  
06:51AM  
02:38AM  
Oct-06-21 04:28PM  
02:32PM  
11:42AM  
10:34AM  
08:28AM  
07:10AM  
Oct-05-21 06:09AM  
05:55AM  
05:11AM  
Oct-04-21 06:30PM  
12:10PM  
11:17AM  
11:07AM  
11:03AM  
10:44AM  
09:56AM  
09:54AM  
08:10AM  
06:38AM  
02:58AM  
Oct-03-21 06:51PM  
Oct-02-21 08:00AM  
Oct-01-21 04:47PM  
04:38PM  
04:16PM  
04:07PM  
03:57PM  
03:44PM  
02:39PM  
01:55PM  
12:41PM  
11:20AM  
10:54AM  
10:08AM  
09:14AM  
08:12AM  
06:55AM  
06:05AM  
02:00AM  
Sep-30-21 05:02PM  
04:07PM  
03:06PM  
01:29PM  
11:31AM  
10:46AM  
07:33AM  
Sep-29-21 05:45PM  
11:02AM  
08:47AM  
06:38AM  
Sep-28-21 05:12PM  
05:10PM  
03:13PM  
11:57AM  
11:24AM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.